In the "Dirty Money" series on Netflix, the "Drug Short" episode (1) helped me understand some of the economic forces that may have influenced T3 / Liothyronine price hikes in the UK. It makes me concerned about the future of T3 pricing in Canada too. This episode focuses on Valeant, a Canadian pharmaceutical company that … Continue reading Dirty Money “Drug Short” episode and thyroid T3 Liothyronine
Top Posts
Blog Stats
- 711,727 hits